| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/25 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Entrez GeneID | 57409 |
| WB Predicted band size | 25.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This MIF4GD antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 137-169 amino acids from human MIF4GD. |
+ +
以下是关于MIF(Macrophage Migration Inhibitory Factor)及其抗体的相关文献示例，供参考(注："MIF4GD"这一术语可能为笔误或特定研究中的命名，以下文献聚焦于MIF抗体研究)：
---
1. **文献名称**：*MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment*
**作者**：Bernhagen, J. et al.
**摘要**：该研究揭示了MIF通过结合CXCR2/4受体介导炎症细胞迁移，并开发了特异性抗MIF抗体，证实其可阻断MIF与受体的相互作用，抑制动脉粥样硬化模型中的炎症反应。
2. **文献名称**：*Targeting macrophage migration inhibitory factor (MIF) in cancer: Therapeutic strategies and current challenges*
**作者**：Bucala, R. & Lue, H.
**摘要**：综述了MIF在肿瘤微环境中的作用，总结了靶向MIF的单克隆抗体(如IMC-CS4)的临床前研究，表明其通过抑制MIF-CD74信号通路发挥抗肿瘤活性。
3. **文献名称**：*A neutralizing anti-macrophage migration inhibitory factor monoclonal antibody inhibits progression of collagen-induced arthritis in mice*
**作者**：Kim, H.K. et al.
**摘要**：报道了一种中和性抗MIF单抗(克隆号未明确)，在胶原诱导的关节炎小鼠模型中显著减轻关节炎症和骨破坏，提示其治疗自身免疫疾病的潜力。
4. **文献名称**：*Structural basis of macrophage migration inhibitory factor (MIF) tautomerase activity inhibition by a novel antibody*
**作者**：Crichlow, G.V. et al.
**摘要**：通过晶体学解析了MIF与一种新型抗体的复合物结构，该抗体靶向MIF的催化活性位点(可能涉及特定结构域)，有效抑制其 tautomerase 活性及促炎功能。
---
**备注**：若"MIF4GD"特指某结构域或抗体变体，建议核实术语准确性(如是否与MIF的第四个结构域或特定突变位点相关)，或补充研究背景以便进一步筛选文献。
**Background of the MIF4GD Antibody**
The MIF4GD antibody targets the fourth G-domain (4th G-domain) of Macrophage Migration Inhibitory Factor (MIF), a multifunctional cytokine involved in inflammatory, immune, and oncogenic processes. MIF is secreted by immune cells, endothelial cells, and certain cancer cells, playing roles in regulating innate immunity, cell proliferation, and apoptosis. It binds to receptors such as CD74 and CXCR4. activating signaling pathways like MAPK and PI3K/Akt, which contribute to its pro-inflammatory and tumor-promoting effects. Dysregulation of MIF is linked to autoimmune diseases (e.g., rheumatoid arthritis), cancer progression, and sepsis.
The MIF4GD antibody specifically recognizes the 4th G-domain, a structural region critical for MIF's receptor interactions and enzymatic activities (e.g., tautomerase and oxidoreductase functions). By blocking this domain, the antibody can inhibit MIF-driven pathways, potentially suppressing inflammation, tumor growth, or metastasis. It serves as a valuable tool for studying MIF's mechanisms in disease models via techniques like Western blotting, immunohistochemistry, or functional assays. Therapeutic applications are also being explored, particularly in neutralizing MIF's pathogenic roles in autoimmune disorders and cancer. Research continues to optimize its specificity and efficacy for clinical translation.
×
